we could not fined enough patients for the study

Sympathetic system has important role occurrence of symptoms in heart failure. Renal denervation that is ablated some of sympathetic nerves is affected pathology of heart failure. This interventional therapy improves symptoms and life quality.

Primary Outcome Measures:

• Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events

Secondary Outcome Measures:

• Ventricular function,NYHA functional Class, 6 min walking test, biochemical test and Renal function as measured by Glomerular Filtration Rate (GFR)

Eligibility Patients population: Volunteers, NYHA Class III-IV heart failure patients. Ages Eligible for Study: 18 Years to 85 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No

Inclusion Criteria:

• Heart Failure patients NYHA Class III or IV
• Left Ventricular Ejection Function < 35%
• GFR > 45 mL/min/1.73m2
• Optimal stable medical therapy

Exclusion Criteria:

• Do not eligible renal artery anatomy for treatment as determined by Angiography, and
• History of prior renal artery intervention
• Single functioning kidney.
• Myocardial Infarction, unstable angina pectoris or cerebrovascular Accident within 3 months
• Systolic BP < 110mmHG Hospitalisation because of heart failure in last 3 weeks.